scholarly journals Treating HIV Encephalopathy with Antiretroviral Therapy: A Clinical Case Demonstrating the Success of HAART

2004 ◽  
Vol 39 (10) ◽  
pp. 1545-1547 ◽  
Author(s):  
P. Shah ◽  
R. Paul ◽  
R. Gold ◽  
K. Tashima ◽  
T. Flanigan
Keyword(s):  
Antiretroviral Therapy ◽  
Clinical Case ◽  
Hiv Encephalopathy

Recovery of HIV encephalopathy in perinatally infected children on antiretroviral therapy

2020 ◽  
Vol 62 (11) ◽  
pp. 1309-1316
Author(s):  
Steve Innes ◽  
Barbara Laughton ◽  
Ronald Toorn ◽  
Kennedy Otwombe ◽  
Afaaf Liberty ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hiv Encephalopathy ◽  
Perinatally Infected

scholarly journals Graves’ disease in HIV patient receiving antiretroviral therapy

2020 ◽  
Vol 66 (3) ◽  
pp. 22-26
Author(s):  
Tatyana B. Morgunova ◽  
Anastasia A. Zorina ◽  
Ekaterina S. Maloletkina ◽  
Yulia P. Sytch ◽  
Ariadna V. Vasileva ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Thyroid Hormones ◽  
Highly Active Antiretroviral Therapy ◽  
Immune Reconstitution ◽  
Clinical Case ◽  
Graves Disease ◽  
Thyroid Disorders ◽  
Immune Reconstitution Syndrome ◽  
Highly Active ◽  
The World

The article focuses on the clinical case of Graves disease in a patient with HIV infection who is receiving antiretroviral therapy. The number of HIV-infected patients has increased significantly in recent decades all over the world. The currently used highly active antiretroviral therapy can significantly improve the prognosis for these patients. However, its use is associated with a number of complications, in particular the development of immune reconstitution syndrome, under which the development of such autoimmune diseases as Graves disease, polymyositis and Guillain-Barre syndrome may occur. Therefore, we would like to draw the attention of doctors to the possibility of such a complication in patients receiving antiretroviral therapy. Timely diagnosis and treatment of thyroid disorders will help to avoid the complications associated with an excess or deficit of thyroid hormones.

scholarly journals 366. Severe Neurologic Impairment Persists Despite Potent ART in HIV Encephalopathy

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S192-S192
Author(s):  
Riley Cutler ◽  
Sarah Trentman ◽  
Roman Jandarov ◽  
Jennifer Brown ◽  
Kevin Robertson ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
The United States ◽  
Summary Score ◽  
Median Viral Load ◽  
Cross Sectional ◽  
Hiv Encephalopathy ◽  
Viral Loads ◽  
Neurocognitive Assessment ◽  
Psychiatric Disturbances ◽  
Diagnosis Of Dementia

Abstract Background Approximately 4–8% of the 1.1 million HIV patients in the United States have or will be diagnosed with HIV encephalopathy or HIV associated dementia (HAD). There are no published studies of the long-term outcomes of HAD treated with potent antiretroviral therapy (ART). We hypothesize that more than 60% of individuals diagnosed with HAD will have persistent neurocognitive impairment despite the successful use of potent ART and fewer than 20% will be employed. Methods This is a cross-sectional prospective and retrospective study of outcomes in individuals previously diagnosed with HAD. We identified all individuals with the diagnosis of dementia and HIV at the UC Infectious Diseases Center (IDC). For those who matched the 1993 CDC HAD definition, we collected medical, neurocognitive, and functional information. We attempted to contact all individuals alive and still in the IDC practice (N = 26) to perform a validated battery of neuropsychological tests. We excluded individuals with HIV-associated neurocognitive disease that developed after treatment with ART. Results We confirmed 39 diagnoses of HAD out of 137 records reviewed. The median CD4 count at the time of diagnosis of HAD was 47 cells/mm3 with a median viral load of 211,475 copies/mL. The median length of follow-up after diagnosis of HAD was 72 months (range 1–166 months). Potent ART was prescribed to all individuals, with 67.5% reaching consistent undetectable viral loads (< 200 copies/mL, occasional blips allowed). Persistent neurologic deficits were noted in 32.5%, while 60% had persistent cognitive deficits. Psychiatric disturbances were present in 72.5%. Only 2.5% reported any employment. To date, 28% have died. Ten participants have undergone formal neurocognitive testing to date (N = 26 available). The median overall summary score (total Z score) was -1.17 (range 0.08, -1.95) and median global deficit (GDS) score was 1.48 (range 0, 2.92). Conclusion HIV-associated dementia results in substantial morbidity and mortality despite potent antiretroviral therapy. Prospective neurocognitive assessment documents significant impairments in most individuals. HIV-associated dementia will require additional strategies to mitigate the profound impact on the quality of life and longevity. Disclosures All authors: No reported disclosures.

scholarly journals HIV encephalopathy presenting as schizophrenia-like delusions during highly active antiretroviral therapy (HAART) case report

2011 ◽  
Vol 01 (03) ◽  
pp. 132-136
Author(s):  
Mikako Fuji ◽  
Misaki Iseki ◽  
Seisho Takeuchi ◽  
Kyoko Kakeda ◽  
Shinji Shimodera ◽  
...  
Keyword(s):  
Case Report ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Hiv Encephalopathy ◽  
Highly Active
Sign in / Sign up

Export Citation Format

Share Document